<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombolytic <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy with tissue plasminogen activator (tPA) is limited by serious risks of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, the authors show that a novel antiactin-targeted immunoliposome significantly reduced tPA-induced <z:mp ids='MP_0001914'>hemorrhage</z:mp> in an established rat model of embolic focal <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Spontaneously hypertensive rats were subjected to focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> using homologous blood clot emboli </plain></SENT>
<SENT sid="3" pm="."><plain>Delayed administration of tPA (10 mg/kg, 6 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) induced <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> at 24 hours </plain></SENT>
<SENT sid="4" pm="."><plain>In control rats treated with tPA plus vehicle, <z:mp ids='MP_0001914'>hemorrhage</z:mp> volumes were 9.0 +/- 2.4 uL (n = 7) </plain></SENT>
<SENT sid="5" pm="."><plain>In rats treated with tPA plus antiactin immunoliposomes, <z:mp ids='MP_0001914'>hemorrhage</z:mp> volumes were significantly reduced to 4.8 +/- 2.7 uL (n = 8, P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>No significant effects were seen when rats were treated with tPA plus a nontargeted liposome (7.8 +/- 2.1 uL, n = 9) </plain></SENT>
<SENT sid="7" pm="."><plain>Fluorescent immunohistochemistry showed that rhodamine-labeled targeted liposomes colocalized with vascular structures in ischemic brain that stained positive for endothelial barrier antigen, a marker of cerebral endothelial cells </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that immunoliposomes may ameliorate vascular membrane damage and reduce hemorrhagic transformation after thrombolytic therapy in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>